Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorÁlamo, Mª del Carmen
dc.contributor.authorOchenduszko, Sebastian
dc.contributor.authorCrespo, Guillermo
dc.contributor.authorCorral, Mónica
dc.contributor.authorOramas, Juana
dc.contributor.authorSancho, Pilar
dc.contributor.authorMuñoz Couselo, Eva
dc.date.accessioned2022-05-13T12:39:16Z
dc.date.available2022-05-13T12:39:16Z
dc.date.issued2021-11-27
dc.identifier.citationÁlamo MC, Ochenduszko S, Crespo G, Corral M, Oramas J, Sancho P, et al. Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-MutatedMetastatic Melanoma in Routine Clinical Practice. Onco Targets Ther. 2021 Nov 27;14:5345-5352.
dc.identifier.issn1178-6930
dc.identifier.urihttp://hdl.handle.net/11351/7530
dc.descriptionBRAF; Cobimetinib; Vemurafenib
dc.description.abstractBackground: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings. Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAFV600 mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PR < 12 months). Secondary endpoints included treatment adherence, labor productivity, anxiety/depression, and safety profile. Results: During the combination therapy, 12 patients (29.3%) had a CR, 19 a PR (46.3%), 5 showed SD (12.2%), and 5 had PD. A total of 12 patients (29.3%) were considered as achieving a durable response and 29 (70.7%) as a non-durable one. Practically all sociodemographic and clinical characteristics were similar between patients. Body mass index was the only differential factor (with higher body mass index achieving a non-durable response). The treatment adherence was 100% in patients with durable response and 66.7% in those with non-durable. Conclusion: The combination treatment with vemurafenib/cobimetinib results in an important impact on long-term survival, leading to a steady CR in one-third of the patients.
dc.language.isoeng
dc.publisherDove Medical Press
dc.relation.ispartofseriesOncoTargets and Therapy;14
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectMelanoma - Tractament
dc.subjectMetàstasi
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshMelanoma
dc.subject.mesh/drug therapy
dc.subject.meshNeoplasm Metastasis
dc.subject.meshTreatment Outcome
dc.titleDurable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2147/OTT.S325208
dc.subject.decsmelanoma
dc.subject.decs/farmacoterapia
dc.subject.decsmetástasis neoplásica
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.2147/OTT.S325208
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Álamo MC] Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Ochenduszko S] Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain. [Crespo G] Oncology Department, Hospital Universitario de Burgos, Burgos, Spain. [Corral M] Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Oramas J] Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Sancho P] Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Muñoz-Couselo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34866914
dc.identifier.wos000723709200002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record